Public hesitancy to COVID-19 vaccine and the role of pharmacists in addressing the problem and improving uptake.
COVID‐19
clinical pharmacists
pharmacists
pharmacy practice
vaccine hesitancy
Journal
Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia
ISSN: 2055-2335
Titre abrégé: J Pharm Pract Res
Pays: Australia
ID NLM: 101145354
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
25
05
2021
revised:
22
10
2021
accepted:
28
10
2021
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
ppublish
Résumé
COVID-19 is one of the worst pandemics in recent human history, causing huge health, economic, and psychosocial damage. Since the pandemic hit, several unsubstantiated claims regarding exposure, transmission and management have been disseminated. Misinformation and associated public confusion now extend to the COVID-19 vaccines, spanning from claims based on possible links between some vaccine types and rare blood clots, to baseless claims. As a result, the public's trust in COVID-19 vaccines has been eroded, fuelling an already troubling trend of vaccine hesitancy. As medication experts and the most accessible healthcare providers, pharmacists are well equipped with the required skills and knowledge to improve COVID-19 vaccine uptake by taking roles that range from dispelling myths, to providing reliable evidence-based information, through to vaccine administration. This paper discusses public hesitancy to COVID-19 vaccines, major contributing factors, and the role pharmacists can play in reducing hesitancy and increasing vaccine uptake.
Identifiants
pubmed: 35464639
doi: 10.1002/jppr.1784
pii: JPPR1784
pmc: PMC9015492
doi:
Types de publication
Journal Article
Langues
eng
Pagination
494-500Informations de copyright
© 2021 Society of Hospital Pharmacists of Australia.
Déclaration de conflit d'intérêts
The authors declare that there are no financial or other relationships that might lead to a conflict of interest.
Références
J Pharm Policy Pract. 2016 Oct 19;9:32
pubmed: 27777781
Vaccine. 2020 Oct 21;38(45):7049-7056
pubmed: 32980199
Res Social Adm Pharm. 2021 Feb;17(2):300-306
pubmed: 32295736
Res Social Adm Pharm. 2021 Jan;17(1):1954-1963
pubmed: 32387230
Soc Sci Med. 2020 Nov;265:113414
pubmed: 33038683
Mayo Clin Proc. 2021 Mar;96(3):699-707
pubmed: 33673921
BMC Public Health. 2021 Apr 28;21(1):818
pubmed: 33910558
BMJ Open. 2021 Jun 16;11(6):e050043
pubmed: 34135054
Pers Individ Dif. 2020 Nov 1;166:110201
pubmed: 32565592
Hum Vaccin Immunother. 2020;16(1):70-75
pubmed: 31369322
J Behav Med. 2014 Apr;37(2):218-33
pubmed: 23188480
Vaccines (Basel). 2020 Dec 30;9(1):
pubmed: 33396832
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Vaccine. 2020 Nov 10;38(48):7668-7673
pubmed: 33071002